Bioartificial pancreas. Microencapsulation and conformal coating of islet of Langerhans

Advanced Drug Delivery Reviews

Volumn 62, Issue 7-8, 2010, Pages 827-840

  Teramura, Yuji ^a   Iwata, Hiroo ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Bioartficial pancreas; Cell transplantation; Conformal coating; Encapsulation; Islet; Islet transplantation; Surface modification

Indexed keywords

CELL TRANSPLANTATION; CONFORMAL COATINGS; ISLET TRANSPLANTATION; PANCREAS CELLS; SURFACE MODIFICATION;

DRUG INTERACTIONS; DRUG THERAPY; ENCAPSULATION;

COATINGS;

AGAROSE; ALGINIC ACID; DIMETHYL SULFOXIDE; ETHYLENE GLYCOL; GLUCOSE; MACROGOL; POLITEF; POLY(ALLYLAMINE HYDROCHLORIDE); POLYETHYLENEIMINE; POLYLYSINE; POLYMER; POLYSTYRENE; POLYVINYL ALCOHOL; POTASSIUM DIHYDROGEN PHOSPHATE; POVIDONE; UNCLASSIFIED DRUG;

ARTIFICIAL PANCREAS; BIOARTIFICIAL ORGAN; CRYOPRESERVATION; EXPERIMENTAL MODEL; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; HYDROGEL; HYDROPHOBICITY; INSULIN DEPENDENT DIABETES MELLITUS; MEMBRANE PERMEABILITY; MICROENCAPSULATION; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; POROSITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; BIOARTIFICIAL ORGANS; CELL TRANSPLANTATION; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS, ARTIFICIAL;

EID: 77953688274     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.01.005     Document Type: Review

References (67)

1. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 2000, 343:230-238.
2. Ryan E.A., Lakey J.R., Rajotte R.V., Korbutt G.S., Kin T., Imes S., Rabinovitch A., Elliott J.F., Bigam D., Kneteman N.M., Warnock G.L., Larsen I., Shapiro A.M. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001, 50:710-719.
3. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
4. Kizilel S., Garfinkel M., Opara E. The bioartificial pancreas: progress and challenges. Diabetes Technol. Ther. 2005, 7:968-985.
5. Wilson J.T., Chaikof E.L. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv. Drug Deliv. Rev. 2008, 60:124-145.
6. Narang A.S., Mahato R.I. Biological and biomaterial approaches for improved islet transplantation. Pharmacol. Rev. 2006, 58:194-243.
7. de Vos P., Faas M.M., Strand B., Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006, 27:5603-5617.
8. Archer J., Kaye R., Mutter G. Control of streptozotocin diabetes in Chinese hamsters by cultured mouse islet cells without immunosuppression: a preliminary report. J. Surg. Res. 1980, 28:77-85.
9. Hirotani S., Eda R., Kawabata T., Fuchinoue S., Teraoka S., Agishi T., Ohgawara H. Bioartificial endocrine pancreas (Bio-AEP) for treatment of diabetes: effect of implantation of Bio-AEP on the pancreas. Cell Transplant. 1999, 8:399-404.
10. Lee S.H., Hao E., Savinov A.Y., Geron I., Strongin A.Y., Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 2009, 87:983-991.
11. Lacy P.E., Hegre O.D., Gerasimidi-Vazeou A., Gentile F.T., Dionn K.E. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991, 254:1782-1784.
12. Maki T., Ubhi C.S., Sanchez-Farpon H., Sullivan S.J., Borland K., Muller T.E., Solomon B.A., Chick W.L., Monaco A.P. Successful treatment of diabetes with the biohybrid artificial pancreas in dogs. Transplantation 1991, 51:43-51.
13. Monaco A.P., Maki T., Ozato H., Carretta M., Sullivan S.J., Borland K.M., Mahoney M.D., Chick W.L., Muller T.E., Wolfrum J., et al. Transplantation of islet allografts and xenografts in totally pancreatectomized diabetic dogs using the hybrid artificial pancreas. Ann. Surg. 1991, 214:339-362.
14. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210:908-910.
15. O'Shea G.M., Goosen M.F.A., Sun A.M. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim. Biophys. Acta 1984, 804:133-136.
16. 2+-alginate-coated islets of Langerhans for immunoisolation. Exp. Clin. Endocrinol. 1994, 102:380-387.
17. Sun Y.L., Ma X.J., Zhou D.B., Vacek I., Sun A.M. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Invest. 1996, 98:1417-1422.
18. Iwata H., Takagi T., Amemiya H., Shimizu H., Yamashita K., Kobayashi K., Akutsu T. Agarose for a bioartificial pancreas. J. Biomed. Mater. Res. 1992, 26:967-977.
19. Iwata H., Kobayashi K., Takagi T., Oka T., Yang H., Amemiya H., Tsuji T., Ito F. Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. J. Biomed. Mater. Res. 1994, 28:1003-1011.
20. Iwata H., Takagi T., Kobayashi K., Oka T., Tsuji T., Ito F. Strategy for developing microbeads applicable to islet xenotransplantation into a spontaneous diabetic NOD mouse. J. Biomed. Mater. Res. 1994, 28:1201-1207.
21. Kin T., Iwata H., Aomatsu Y., Ohyama T., Kanehiro H., Hisanaga M., Nakajima Y. Xenotransplantation of pig islets in diabetic dogs with use of a microcapsule composed of agarose and polystyrene sulfonic acid mixed gel. Pancreas 2002, 25:94-100.
22. Kobayashi T., Aomatsu Y., Iwata H., Kin T., Kanehiro H., Hisanaga M., Ko S., Nagao M., Nakajima Y. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression. Transplantation 2003, 75:619-625.
23. Rajotte R.V., Stewart H.L., Voss W.A.G., Shnitka T.K. Viability studies on frozen-thawed rat islets of Langerhans. Cryobiology 1977, 14:116-120.
24. Rajotte R.V., Warnock G.L., Kneteman N.N. Cryopreservation of insulin-producing tissue in rats and dogs. World J. Surg. 1984, 8:179-186.
25. Rajotte R.V., Warnock G.L., Kneteman N.N., Erickson C., Ellis D.K. Optimizing cryopreservation of isolated islets. Transplant. Proc. 1989, 21:2638-2640.
26. von Mach M.A., Schlosser J., Weiland M., Feilen P.J., Ringel M., Hengstler J.G., et al. Size of pancreatic islets of Langerhans: a key parameter for viability after cryopreservation. Acta Diabetol. 2003, 40:123-129.
27. Matsumoto S., Matsusita M., Morita T., Kamachi H., Tsukiyama S., Furukawa Y., et al. Effects of synthetic antifreeze glycoprotein analogue on islet cell survival and function during cryopreservation. Cryobiology 2006, 52:90-98.
28. Inaba K., Zhou D., Yang B., Vacek I., Sun A.M. Normalization of diabetes by xenotransplantation of cryopreserved microencapsulated pancreatic islets. Application of a new strategy in islet banking. Transplantation 1996, 61:175-179.
29. Stiegler P.B., Stadlbauer V., Schaffellner S., Halwachs G., Lackner C., Hauser O., Iberer F., Tscheliessnigg K. Cryopreservation of insulin-producing cells microencapsulated in sodium cellulose sulfate. Transplant. Proc. 2006, 38:3026-3030.
30. Agudelo C.A., Iwata H. The development of alternative vitrification solutions for microencapsulated islets. Biomaterials 2008, 29:1167-1176.
31. Agudelo C.A., Teramura Y., Iwata H. Cryopreserved agarose-encapsulated islets as bioartificial pancreas: a feasibility study. Transplantation 2009, 87:29-34.
32. Soon-Shiong P., Heintz R.E., Merideth N., Yao Q.X., Yao Z., Zheng T., Murphy M., Moloney M.K., Schmehl M., Harris M., et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 1994, 343:950-951.
33. Valdés-González R.A., Dorantes L.M., Garibay G.N., Bracho-Blanchet E., Mendez A.J., Dávila-Pérez R., Elliott R.B., Terán L., White D.J. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur. J. Endocrinol. 2005, 153:419-427.
34. Calafiore R., Basta G., Luca G., Lemmi A., Montanucci M.P., Calabrese G., Racanicchi L., Mancuso F., Brunetti P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006, 29:137-138.
35. Calafiore R., Basta G., Luca G., Boselli C., Bufalari A., Bufalari A., Cassarani M.P., Giustozzi G.M., Brunetti P. Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians. Ann. N. Y. Acad. Sci. 1999, 875:219-232.
36. Krol S., del Guerra S., Grupillo M., Diaspro A., Gliozzi A., Marchetti P. Multilayer nanoencapsulation. New approach for immune protection of human pancreatic islets. Nano Lett. 2006, 6:1933-1939.
37. Miura S., Teramura Y., Iwata H. Encapsulation of islets with ultra-thin polyion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane. Biomaterials 2006, 27:5828-5835.
38. Scott M.D., Murad K.L., Koumpouras F., Talbot M., Eaton J.W. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7566-7571.
39. Hashemi-Najafabadi S., Vasheghani-Farahani E., Shojaosadati S.A., Rasaee M.J., Armstrong J.K., Moin M., Pourpak Z. A method to optimize PEG-coating of red blood cells. Bioconjug. Chem. 2006, 17:1288-1293.
40. Nacharaju P., Boctor F.N., Manjula B.N., Acharya S.A. Surface decoration of red blood cells with maleimidophenyl-polyethylene glycol facilitated by thiolation with iminothiolane: an approach to mask A, B, and D antigens to generate universal red blood cells. Transfusion 2005, 45:374-383.
41. Chen A.M., Scott M.D. Immunocamouflage: prevention of transfusion induced graft-versus-host disease via polymer grafting of donor cells. J. Biomed. Mater. Res. A 2003, 67:626-636.
42. Murad K.L., Gosselin E.J., Eaton J.W., Scott M.D. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Blood 1999, 94:2135-2141.
43. Contreras J.L., Xie D., Mays J., Smyth C.A., Eckstein C., Rahemtulla F.G., Young C.J., Anthony J.T., Bilbao G., Curiel D.T., Eckhoff D.E. A novel approach to xenotransplantation combining surface engineering and genetic modification of isolated adult porcine islets. Surgery 2004, 136:537-547.
44. Lee D.Y., Lee S., Nam J.H., Byun Y. Minimization of immunosuppressive therapy after islet transplantation: combined action of heme oxygenase-1 and PEGylation to islet. Am. J. Transplant. 2006, 6:1820-1828.
45. Lee D.Y., Nam J.H., Byun Y. Functional and histological evaluation of transplanted pancreatic islets immunoprotected by PEGylation and cyclosporine for 1year. Biomaterials 2007, 28:1957-1966.
46. Teramura Y., Kaneda Y., Iwata H. Islet-encapsulation in ultra-thin layer-by-layer membranes of poly(vinyl alcohol) anchored to poly(ethylene glycol)-lipids in the cell membrane. Biomaterials 2007, 28:4818-4825.
47. Teramura Y., Kaneda Y., Totani T., Iwata H. Behavior of synthetic polymers immobilized on cell membrane. Biomaterials 2008, 29:1345-1355.
48. Teramura Y., Iwata H. Islets surface modification prevents blood-mediated inflammatory responses. Bioconjug. Chem. 2008, 19:1389-1395.
49. Teramura Y., Iwata H. Islet encapsulation with living cells for improvement of biocompatibility. Biomaterials 2009, 30:2270-2275.
50. Teramura Y., Iwata H. Surface modification of islets with PEG-lipid for improvement of graft survival in intraportal transplantation. Transplantation 2009, 88:624-630.
51. Totani T., Teramura Y., Iwata H. Immobilization of urokinase to islet surface by amphiphilic poly (vinyl alcohol) carrying alkyl side chains. Biomaterials 2008, 29:2878-2883.
52. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. 1995, 6:150-165.
53. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipatic poly(ethylene glycol)s effectively prolong the circulation time of liposome. FEBS Lett. 1990, 268:235-237.
54. Paulick M.G., Forstner M.B., Groves J.T., Bertozzi C.R. A chemical approach to unraveling the biological function of the glycosylphosphatidylinositol anchor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20332-20337.
55. Rabuka D., Forstner M.B., Groves J.T., Bertozzi C.R. Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes. J. Am. Chem. Soc. 2008, 130:5947-5953.
56. Korsgren O., Lundgren T., Felldin M., Foss A., Isaksson B., Permert J., Persson N.H., Rafael E., Rydén M., Salmela K., Tibell A., Tufveson G., Nilsson B. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 2008, 51:227-232.
57. Moberg L., Johansson H., Lukinius A., Berne C., Foss A., Kallen R., Ostraat O., Salmela K., Tibell A., Tufveson G., Elgue G., Ekdahl K., Korsgren O., Nilsson B. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
58. Contreras J.L., Eckstein C., Smyth C.A., Bilbao G., Vilatoba M., Ringland S.E., Young C., Thompson J.A., Fernandez J.A., Griffin J.H., Eckhoff D.E. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004, 53:2804-2814.
59. Johansson H., Lukinius A., Moberg L., Lundgren T., Berne C., Foss A., Felldin M., Kallen R., Salmela K., Tibell A., Tufveson G., Ekdahl K.N., Elgue G., Korsgren O., Nilsson B. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005, 54:1755-1762.
60. Bennet W., Sundberg B., Lundgren T., Tibell A., Groth C.G., Richards A., White D.J., Elgue G., Larsson R., Nilsson B., Korsgren O. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 2000, 69:711-719.
61. Bennet W., Sundberg B., Groth C.G., Brendel M.D., Brandhorst D., Brandhorst H., Bretzel R.G., Elgue G., Larsson R., Nilsson B., Korsgren O. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?. Diabetes 1999, 48:1907-1914.
62. Cabric S., Sanchez J., Lundgren T., Foss A., Felldin M., Kallen R., Salmela K., Tibell A., Tufveson G., Larsson R., Korsgren O., Nilsson B. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007, 56:2008-2015.
63. Stabler C.L., Sun X.L., Cui W., Wilson J.T., Haller C.A., Chaikof E.L. Surface re-engineering of pancreatic islets with recombinant azido-thrombomodulin. Bioconjug. Chem. 2007, 18:1713-1715.
64. Pollok J.M., Lorenzen M., Kölln P.A., Török E., Kaufmann P.M., Kluth D., et al. In vitro function of islets of Langerhans encapsulated with a membrane of porcine chondrocytes for immunoisolation. Dig. Surg. 2001, 18:204-210.
65. Lee J.I., Nishimura R., Sakai H., Sasaki N., Kenmochi T. A newly developed immunoisolated bioartificial pancreas with cell sheet engineering. Cell Transplant. 2008, 17:51-59.
66. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., Lakey J.R., Shapiro A.M. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
67. Robertson R.P., Lanz K.J., Sutherland D.E., Kendall D.M. Prevention of diabetes for up to 13years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001, 50:47-50.